Cancer by Muffly, Lori et al.
Adoption of Pediatric-Inspired Acute Lymphoblastic Leukemia 
Regimens by Adult Oncologists Treating Adolescents and Young 
Adults: A Population-Based Study
Lori Muffly, MD MS1,6, Daphne Lichtensztajn, MD, MPH2, Parveen Shiraz, MD1, Renata 
Abrahão, MD, MSc2, Jennifer McNeer, MD MS3, Wendy Stock, MD4, Theresa Keegan, PhD5, 
and Scarlett Lin Gomez, PhD2,6
1Stanford University, Dept. of Medicine, Division of Blood and Marrow Transplantation, Stanford, 
CA
2Cancer Prevention Institute of California, Freemont, CA
3University of Chicago, Department of Pediatrics, Section of Hematology/Oncology, Chicago, IL
4University of Chicago, Dept. of Medicine, Section of Hematology/Oncology, Chicago, IL
5University of California Davis School of Medicine, Dept. of Medicine, Division of Hematology/
Oncology, Sacramento, CA
6Stanford Cancer Institute, Stanford University, Stanford CA
Abstract
Background—Studies show superior outcomes for adolescent and young adult (AYA) patients 
with acute lymphoblastic leukemia (ALL) treated following pediatric versus adult ALL therapeutic 
regimens. Whether adult oncologists in the United States have adopted this approach to AYA ALL 
is currently unknown. We sought to provide a population-based description of AYA ALL treatment 
patterns over the past decade.
Methods—Data on AYAs 15-39 years and diagnosed with ALL during 2004-2014 while living in 
the Greater Bay Area were obtained from the Greater Bay Area Cancer Registry (GBACR). 
Treating facilities were designated as pediatric or adult centers; induction treatment regimens were 
abstracted from registry text data fields.
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Results—Of 304 patients diagnosed in the GBACR catchment region, complete treatment data 
was available for 229 (75%). Location of care was identified for 296 (97%) patients treated at 31 
unique centers. 70% of AYAs received induction therapy at an adult center. All AYAs treated at 
pediatric centers received pediatric ALL regimens. Among AYAs treated by adult oncologists with 
complete treatment data, none received a pediatric regimen prior to 2008. From 2008-2012, while 
the adult intergroup C10403 pediatric-inspired ALL protocol was open to accrual, 31% of AYAs 
treated by adult oncologists received pediatric regimens. This fell to 21% in 2013-2014. Adult 
facilities treating ≥2 AYA ALL GBACR patients per year were more likely to administer pediatric 
regimens than lower volume centers (P= 0.03).
Conclusion—As of 2014, only a minority of AYAs with ALL received pediatric ALL regimens 
at adult cancer centers.
Introduction
Over the past decade, a large body of research has focused on discrepancies in the treatment 
approach and survival of adolescents and young adults (AYAs) with acute lymphoblastic 
leukemia (ALL) treated in the pediatric versus adult setting. A multitude of retrospective 
analyses from United States (U.S.) and European cooperative groups conclude that, 
independent of traditional ALL risk factors, AYAs with ALL have markedly superior 
outcomes when treated by pediatric oncologists following pediatric treatment protocols.1-5 
In general, pediatric ALL regimens are more intensive and more highly regimented than 
adult regimens, likely contributing to their improved success.6
The intriguing findings from the retrospective studies1-5 led many groups to prospectively 
consider the feasibility and outcomes of pediatric inspired protocols administered to AYAs 
with ALL by adult oncologists.7, 89-13 Recently, preliminary results of U.S. Intergroup study 
C10403, the largest prospective evaluation of a pediatric treatment approach applied by adult 
oncologists to AYAs with ALL have been presented.14 Among 318 AYAs 17-39 years old 
enrolled from 2007-2012, 2-year event-free survival (EFS) and overall survival (OS) were 
66% and 78%, respectively, which was considerably higher than EFS and OS of 34% and 
46% of historical controls treated on US adult cooperative group trials for ALL. 14
With accumulating evidence supporting the notion that AYAs with ALL should be treated 
according to pediatric-inspired protocols, many potential obstacles in the U.S. exist. While 
ALL is the most commonly occurring malignancy in children, ALL occurs less commonly 
in in adults, accounting for only 15% of all leukemia and 0.4% of adult cancer diagnoses in 
the U.S.15 A large proportion of AYA ALL is treated in the community, rather than at 
National Cancer Institute (NCI)-designated Comprehensive Cancer Centers.16 The pediatric-
inspired regimens recommended for AYA ALL include drugs and therapeutic combinations 
that are not routinely used in adult oncology practice; thus, implementation of pediatric-
inspired regimens which require frequent and prolonged outpatient therapy may be daunting 
for adult oncologists who treat a paucity of patients with ALL each year. As one example, 
the delivery of asparaginase throughout the treatment period is critical to the success of 
pediatric ALL regimens, but use of this agent requires familiarity with its potential 
toxicities.17
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The seminal finding that more AYAs with ALL may be cured if treated with pediatric-
inspired regimens is only meaningful if adult oncologists routinely and successfully adopt 
and adhere to these treatment protocols. Thus, to understand changes in the utilization of 
pediatric-inspired ALL regimen over the past decade, we used facility-level data from a 
population-based cancer registry to describe AYA ALL treatment patterns among pediatric 
and adult oncologists.
Methods
Data were abstracted from the population-based Greater Bay Area Cancer Registry 
(GBACR), a part of the California Cancer Registry (CCR) and the National Cancer Institute 
Surveillance, Epidemiology, and End Results (SEER) program. The GBACR includes 
approximately 6.8 million residents of the nine-county Greater Bay Area ([GBA]; Alameda, 
Contra Costa, Marin, Monterey, San Benito, San Francisco, San Mateo, Santa Clara, Santa 
Cruz) who receive a cancer diagnosis within the counties, regardless of health insurance 
status or treating facility. Case selection included all AYAs aged 15-39 years at diagnosis of 
ALL (International Classification of Diseases for Oncology, 3rd edition,18 codes 9826, 
9835, 9836, 9811-9818, 9837 as per SEER site recode for ALL), with diagnosis occurring 
between 2004 and 2014. Because GBACR data were used for this analysis, only GBA 
residents are included; residents outside of the GBACR counties but treated in a facility in 
the GBA region are not included in this analysis. Conversely, a small number of patients 
diagnosed in the GBA but receiving induction therapy outside of the GBACR were included, 
as their treatment data was reported to the GBACR.
Patient and tumor characteristics were obtained from the GBACR (routinely collected for the 
registry via medical record abstraction) including age at diagnosis, sex, race/ethnicity, health 
insurance status at the time of initial diagnosis or treatment, and a previously developed 
composite measure of neighborhood socioeconomic status (SES) that incorporates Census 
block group level data on income, education, housing costs, and employment; patients were 
assigned to statewide SES quintiles based on their address at time of diagnosis.19, 20 Year of 
diagnosis was categorized as 2004-2007, 2008-2012, and 2013-2014, reflecting potentially 
relevant events in AYA ALL, including the accrual period of C10403 from 2008 through 
2012.14
We reviewed all available GBACR facility-level reports for each patient. These facility-level 
reports reflect information reported to the GBACR from each facility, and are normally 
consolidated to the tumor level when reported to SEER. For each patient diagnosed in the 
GBA and captured in the GBACR, initial ALL induction chemotherapy regimen was 
abstracted from a data text field. Treatment regimens included in the analysis were listed by 
name in the registry (e.g. “C9511”, “hypercvad”, etc.). Individuals with registry treatment 
text fields that included only therapeutic agents without specific regimen name (e.g. 
cyclophosphamide, vincristine, doxorubicin, dexamethasone without mention of specific 
regimen) were designated as unclear (neither adult nor pediatric) and were not coded as a 
specific regimen. Induction regimens were categorized as either adult or pediatric/pediatric 
inspired ALL regimens. Adult ALL regimens included hypercvad,21 U.S. adult cooperative 
group regimens (C8811,22 C9511,23 C19802,24 E2993,25 C10701 [NCT01256398], E1910 
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[NCT02003222]) excluding intergroup C10403,14 and the Linker regimen.26 Pediatric/
pediatric-inspired regimens included C10403,14 the Dana-Farber Cancer Institute pediatric-
inspired regimen,11 and any U.S. pediatric cooperative group ALL regimen.
Physicians involved in the care of the patient (attending physician, medical oncologist, 
radiation oncologist, referring physician, follow-up physician, and up to two additional 
physicians) are recorded in the registry. The medical license numbers of all physicians listed 
for each patient were cross-referenced with CCR and GBACR physician databases to obtain 
the physician’s medical specialty. The facility where induction treatment was administered 
(treatment setting) was designated as either a pediatric or adult setting. Patients receiving 
induction in a facility that reports to the GBACR as a stand-alone children’s facility (cross 
referenced with a list of Children’s Oncology Group pediatric cancer centers27 and 
children’s hospitals27 across California) were considered to have been treated in a pediatric 
setting. Patients receiving induction in a facility that does not treat children were considered 
to have been treated in an adult setting. Patients treated at institutions that treat both children 
and adults and do not report cancer cases from their pediatric and adult hospitals separately 
were identified as treated in a pediatric setting only if the treating physician was a pediatric 
oncologist. Cases where treatment setting (pediatric versus adult) could not be clarified 
through this methodology were considered to have unidentifiable treatment setting, and were 
not included in further analyses. Hospitals were classified by their affiliation with an NCI-
designated cancer center, and facility AYA ALL volume during 2004-2014 was calculated 
based on the number of AYA ALL inductions administered by each facility in our dataset. If 
more than one facility reported administering chemotherapy, individual records were 
reviewed to identify the hospital that administered the induction regimen.
Descriptive statistics (frequencies, percentages) characterized baseline patient, hospital, and 
treatment characteristics by treatment settings and regimens. Differences between pediatric 
and adult treatment settings and pediatric and adult ALL regimens administered in adult 
treatment settings were evaluated using Fisher’s exact test. Statistical analyses were 
performed using SAS versions 9.3 and 9.4 (Cary, NC); 2-sided P-values of <0.05 were 
considered statistically significant. This study was approved under the GBACR IRB protocol 
by the Cancer Prevention Institute of California Institutional Review Board.
Results
Patient Characteristics and Treatment Setting
304 AYAs with ALL diagnosed in the GBA during 2004-2014 were identified (see Figure 1 
for cohort diagram). Treatment setting where induction chemotherapy was administered was 
captured for 296 (97%) patients; eight patients for whom treatment setting could not be 
discerned were excluded from additional analyses. Treatment occurred in 31 unique 
facilities. Of these, two were exclusively pediatric facilities and Children’s Oncology Group 
member institutions. An additional eight pediatric facilities that report to the CCR as part of 
a larger institution were identified by the treating physicians’ specialty and practice location. 
Of these, half were Children’s Oncology Group member institutions. The remaining 21 
treatment facilities were exclusively considered to be adult facilities, of which 3 are NCI-
designated cancer centers.
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The majority of AYAs in our study (n=207; 70%) received initial induction therapy in an 
adult setting (Table 1). AYAs treated in the adult setting were older (P<0.0001) and more 
likely to be non-Hispanic White (P= 0.02) than AYAs treated in the pediatric setting. Patients 
treated in an adult setting were less likely to be treated at a facility associated with an NCI-
designated cancer center (P= 0.042), and more likely to be treated at low volume AYA ALL 
centers (P< 0.0001).
Shifts in Treatment Setting over Time
For the youngest AYAs (aged 15-18 years), the majority received therapy in a pediatric 
setting (93%), with no significant changes in treatment setting over time (Figure 2). Older 
AYAs (aged 25-39 years) were exclusively treated in adult settings throughout the decade. 
For AYAs aged 19-24 years, there was a shift towards ALL treatment increasingly being 
delivered in pediatric, as opposed to adult, centers over time (P< 0.0001).
Treatment Regimens Administered to AYAs in Adult Setting
Complete induction regimen data was available for 229 (75%) of the entire cohort. 89 AYAs 
were treated in a pediatric setting from 2004-2014, all of whom received pediatric ALL 
regimens. Most (81%) AYAs received Children’s Oncology Group regimens, either as part 
of clinical trial or as standard of care.
Amongst the 207 AYAs treated in an adult setting, complete induction regimen data was 
available for 149 (72%); 56 (27%) received treatment that could not be clearly identified as a 
pediatric or adult ALL regimen, and 2 patients died prior to treatment administration (Figure 
1). The treatment regimen was increasingly identifiable over time: 57% treated from 
2004-2007,79% treated from 2008-2012, and 81% treated from 2013-2014 had identifiable 
induction regimen data, respectively.
The majority (79%) received adult ALL regimens from 2004 to 2014, with hyperfractionated 
cyclophosphamide, vincristine, doxorubicin, dexamethasone (Hyper-CVAD) being the most 
frequent regimen (Table 2). Prior to 2008, no AYA ALL patients treated in the adult setting 
received a pediatric-inspired ALL regimen. During 2008-2012, while C10403 was open to 
accrual, 25% of the AYAs treated in the adult setting received a pediatric-inspired ALL 
protocol, with most receiving the C10403 regimen either on or off protocol. Following 
closure of C10403, 21% of AYAs treated in the adult setting from 2013 to 2014 received a 
pediatric-inspired ALL regimen.
Factors Associated with Receipt of a Pediatric ALL Regimen in the Adult Setting
AYAs who received a pediatric ALL regimen in the adult setting were more likely to be 
diagnosed between 2008 and 2012 (as opposed to 2004-2007 or 2013-2014), to receive 
induction treatment at an NCI-designated cancer center, and to receive induction treatment at 
a facility that treated ≥2 AYA ALL patients per year (Table 3). In the adult setting, the 
distribution of patient-related variables, such as age, race/ethnicity, neighborhood SES, and 
health insurance status were similar for AYAs who received a pediatric versus adult ALL 
regimen.
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Discussion
AYAs with ALL represent a unique population at a crossroads between pediatric and adult 
oncology. However, the gap between recommended pediatric versus adult approaches to 
AYA ALL has narrowed through retrospective and prospective research demonstrating that 
outcomes for AYAs with ALL are superior when these patients are treated using pediatric-
inspired ALL regimens, regardless of the setting in which they are delivered.1-3, 5, 7-14 
Although this message has been disseminated throughout the oncology literature and 
through clinical guideline summaries and practice recommendations internationally and in 
the U.S.,28, 29 our results based on a population-based case series, show that as recently as 
2014, only a minority of AYAs with ALL who receive care across a wide variety of adult 
oncology facilities in Northern California are treated following pediatric ALL regimens.
There are several likely explanations as to why the adoption of pediatric-inspired ALL 
regimens may be slow within the general adult oncology community in the U.S. As shown 
by others and supported in our results, unlike pediatric ALL, most adult ALL in the U.S. is 
not treated in highly specialized, high volume ALL centers.16 Strikingly, we found that one-
third of AYA ALL patients treated in adult settings are cared for at centers that treat one or 
fewer AYA ALL patients per year. Adult oncologists who rarely treat ALL may be less 
familiar with literature supporting a pediatric treatment approach for AYA ALL. 
Furthermore, they may also be less comfortable with the often challenging schedules and 
drug administration associated with pediatric ALL protocols. In addition, specific pediatric 
ALL regimen related toxicities may be heightened in the AYA population,30, 31 such as 
steroid-induced osteonecrosis, hepatotoxicity and thrombosis related to asparaginase, which, 
if encountered, may lead to an unwillingness to embark upon these intensive ALL regimens 
in other AYAs. Additional work is needed to more clearly understand the knowledge gaps 
and barriers to utilization of pediatric-inspired ALL protocols within the diverse U.S. adult 
oncology community.
In addition to describing oncologist practice patterns, our work provides a general overview 
of where AYAs with ALL are receiving care in the U.S. Not surprisingly, AYAs ≤18 years 
were almost entirely treated at pediatric centers, while AYAs ≥25 years were universally 
cared for in adult treatment settings. What is perhaps most interesting is to examine the 
group of AYAs aged 19-24, who are truly at the intersection between teenage years and 
young adulthood. Our data reveal that this group may be increasingly cared for at pediatric 
centers, or perhaps within AYA programs housed in pediatric centers. Given the small 
sample size of these patients within our dataset this finding should be confirmed in a larger 
cohort. Many have advocated for the creation of AYA-specific programs in order to provide 
age-specific care and to better address the unique toxicities and psychosocial challenges that 
face AYAs with cancer.32, 33 Although our data could not determine care received through 
AYA specialty programs, others have reported an increased use of pediatric regimens 
delivered to ALL patients treated at AYA centers.34
At a minimum, our findings support the notion that AYAs with ALL are more likely to 
receive pediatric ALL regimens at either pediatric centers or at adult centers that treat a 
higher volume of these patients. Our findings that receipt of a pediatric ALL regimen in the 
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adult setting are associated with NCI-cancer center designation and AYA ALL volume is, in 
part, related to the C10403 study, which was open to accrual from 2008 to 2012. Although 
this study was open at larger, academic cancer centers, it was also open to accrual at 
community-based cancer centers. Further, the trend towards use of adult ALL regimens at 
lower volume AYA ALL facilities continued through 2013-2014, supporting the notion that 
even after closure of this national study there continues to be a variety of approaches to the 
treatment of AYA ALL. Our findings suggest that use of pediatric inspired ALL regimens 
for AYA patients treated in the adult setting may rise with the opening of another national 
ALL trial aimed at AYA patients. However, AYA patients treated at low volume ALL centers 
often do not have access to cooperative group studies, thus widening the disparity in 
treatment approaches between centers caring for AYA ALL patients.
Our study intended to describe patterns of AYA ALL treatment with a population-based 
approach. We used choice of induction regimen as a surrogate for treatment approach. For 
most ALL patients the initial ALL regimen is followed throughout the treatment course; 
however, clinical circumstances such as refractory disease or transplantation in first 
remission may alter the treatment course over time. We were limited in that not every patient 
reported to the GBACR had usable induction treatment data, although data capture in over 
70% of patients was more favorable than anticipated, and most patients without usable data 
were treated from 2004 to 2007, when most, if not all, AYAs with ALL were treated using 
adult regimens in the adult setting. Our sample size did not allow for multivariate modeling 
of the independent factors associated with pediatric regimens in the adult setting, which 
would be of interest. Importantly, results based on patients in Northern California may not 
represent AYA ALL patients or practice patterns across the U.S. However, use of a 
population-based dataset enabled us to include AYA ALL patients with a variety of racial/
ethnic and socioeconomic backgrounds, including those who were uninsured, privately 
insured and publicly insured. Patients in our study were treated at 31 hospitals, including 
small community-based and larger, private hospital networks, as well as academic centers, 
similar to the range of AYA cancer treatment locations across the U.S.35 Consolidation of 
AYA cancer care in other countries has been described.36, 37 Finally, we did not intend this 
to be a study of AYA ALL outcomes, as there is already an abundance of retrospective and 
prospective research comparing outcomes for AYA ALL patients treated with pediatric 
versus adult regimens; 1-5, 7-14, 29 rather, our objective was to describe patterns of AYA ALL 
management over time in order to inform clinicians and researchers in the field.
In conclusion, with a population-based approach using patient facility-level data reported to 
the GBACR, we demonstrate general practice patterns related to the treatment of AYA ALL 
in the U.S. over the last decade. Our data show that as recently as 2014, AYAs with ALL 
were treated with a wide variety of ALL treatment protocols, the minority being pediatric-
inspired ALL regimens. Additional research is needed to determine factors that contribute to 
AYA ALL treatment selection by adult oncologists, and to understand barriers to increasing 
AYA care at higher volume AYA ALL centers.
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Figure 1. 
Study Flow Chart
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Figure 2. 
AYA ALL Treatment Setting Over the Past Decade
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Table 2
Treatment Regimens Administered in Adult Settings to AYAs with ALL Diagnosed in the Greater Bay Area 
by Time Period of Diagnosis, 2004-2014
Treatment Regimen Total N=149 2004-2007 N=36 2008-2012 N=84 2013-2014 N=29
Adult ALL Regimen 117 (79%) 36 (100%) 58 (69%) 23 (79%)
 Hypercvad 45 11 23 11
 Adult Cooperative Group 41 16 20 5
 Linker Regimen 26 5 15 6
 Other Adult Regimen 5 <5 0 <5
Pediatric Inspired Regimen 32 (21%) 0 (0%) 26 (31%) 6 (21%)
 C10403 (on or off study) 27 0 24 <5
 Pediatric Cooperative Group 5 0 <5 <5
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